SCHEMBL962168

SCHEMBL962168

CCc1oc(CCc2cc(N3CCOCC3C)cc(NCCOC)n2)nc1C

nearest known ligand 0.75

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 12/20 0.75
KCNH2 Q12809 11/20 0.75
MTOR P42345 6/20 0.38
BRD4 O60885 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL962684 0.81 NPY1R (0.78) NPY1RKCNH2
SCHEMBL12946435 0.81 NPY1R (0.49) NPY1RKCNH2MTORBRD4
SCHEMBL12914799 0.79 KCNH2 (0.69) NPY1RKCNH2
SCHEMBL3408101 0.77 KCNH2 (0.50) NPY1RKCNH2
SCHEMBL962739 0.76 KCNH2 (0.45) NPY1RKCNH2MTOR
SCHEMBL13688201 0.76 KCNH2 (0.64) NPY1RKCNH2
SCHEMBL962911 0.76 NPY1R (0.68) NPY1RKCNH2
SCHEMBL12914798 0.76 NPY1R (0.68) NPY1RKCNH2
SCHEMBL13011978 0.66 NPY1R (0.81) NPY1RKCNH2
SCHEMBL960822 0.66 KCNH2 (0.77) NPY1RKCNH2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-20 US disclosed
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2011-01-20 US disclosed
EP-2264026-A1 ALKYLAMINOPYRIDINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-22 EP disclosed
EP-2264026-A1 ALKYLAMINOPYRIDINE DERIVATIVE Banyu Pharmaceutical Co., Ltd. (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015181-A1 ALKYLAMINOPYRIDINE DERIVATIVE NPY4R, NPY1R, NPY2R NPY1R 2/4885KCNH2 1295/4885MTOR 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.